Journal
EXPERIMENTAL BIOLOGY AND MEDICINE
Volume 243, Issue 3, Pages 213-221Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1535370217750088
Keywords
Biomarkers; cardiovascular; epidemiology; medicine; monitoring; pharmacology; toxicology
Categories
Funding
- Patient-Centered Outcomes Research Institute
- National Institutes of Health
- US Food and Drug Administration
- Amylin
- Eli Lilly and Company
- Bristol-Myers Squibb
- Janssen Research and Development
- Merck
- Novartis
- Amgen
- Bayer Healthcare
- BMEB Services
- Genentech
- GlaxoSmithKline
- Heart. org - Daiichi Sankyo
- Kowa
- Les Laboratoires Servier
- Medscape/Heart. org, Regado
- Roche
Ask authors/readers for more resources
Biomarkers are critical to the rational development of medical therapeutics, but significant confusion persists regarding fundamental definitions and concepts involved in their use in research and clinical practice, particularly in the fields of chronic disease and nutrition. Clarification of the definitions of different biomarkers and a better understanding of their appropriate application could result in substantial benefits. This review examines biomarker definitions recently established by the U.S. Food and Drug Administration and the National Institutes of Health as part of their joint Biomarkers, EndpointS, and other Tools (BEST) resource. These definitions are placed in context of their respective uses in patient care, clinical research, or therapeutic development. We explore the distinctions between biomarkers and clinical outcome assessments and discuss the specific definitions and applications of diagnostic, monitoring, pharmacodynamic/response, predictive, prognostic, safety, and susceptibility/risk biomarkers. We also explore the implications of current biomarker development trends, including complex composite biomarkers and digital biomarkers derived from sensors and mobile technologies. Finally, we discuss the challenges and potential benefits of biomarker-driven predictive toxicology and systems pharmacology, the need to ensure quality and reproducibility of the science underlying biomarker development, and the importance of fostering collaboration across the entire ecosystem of medical product development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available